Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema

Allergy and Asthma Proceedings

Volumn 34, Issue 3, 2013, Pages 267-273

  Gang, Cheng ^a   Lindsell, Christopher J ^a   Moellman, Joseph ^a   Sublett, Wesley ^a   Hart, Kim ^a   Collins, Sean ^b   Bernstein, Jonathan A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; MOEXIPRIL; RAMIPRIL;

ADULT; AFRICAN AMERICAN; AGED; ANGIONEUROTIC EDEMA; ARTICLE; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DYSPNEA; ENDOTRACHEAL INTUBATION; FEMALE; HOSPITALIZATION; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SEASONAL VARIATION; SPRING; TONGUE SWELLING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMBINED MODALITY THERAPY; DRUG HYPERSENSITIVITY; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84878270433     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2013.34.3664     Document Type: Article

References (48)

1. Bernstein JA. Update on angioedema: Evaluation, diagnosis, and treatment. Allergy Asthma Proc 32: 408-412, 2011.
2. Vleeming W, van Amsterdam JG, Stricker BH, and de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention, and management. Drug Saf 18: 171-188, 1998.
3. Vasekar M, and Craig TJ. ACE inhibitor-induced angioedema. Curr Allergy Asthma Rep 12: 72-78.
4. Holm JP, and Ovesen T. Increasing rate of angiotensin-converting enzyme inhibitor-related upper airway angio-oedema. Dan Med J 59:A4449, 2012.
5. Sondhi D, Lippmann M, and Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: Clinical experience at a large community teaching hospital. Chest 126: 400-404, 2004.
6. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 351: 1693-1697, 1998.
7. Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 21: 333-347, 2011.
8. Warner KK, Visconti JA, and Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 34: 526-528, 2000.
9. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17: 103-111, 2004.
10. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of reninangiotensin system inhibitors. Am J Cardiol 110: 383-391.
11. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 15: 1-8, 2012.
12. Brown NJ, Ray WA, Snowden M, and Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 60: 8-13, 1996.
13. Israili ZH, and Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117: 234-242, 1992.
14. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of reninangiotensin system inhibitors. Am J Cardiol 110: 383-391, 2012.
15. Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 100: 327-332, 2008.
16. Agah R, Bandi V, and Guntupalli KK. Angioedema: The role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 23: 793-796, 1997.
17. Megerian CA, Arnold JE, and Berger M. Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment. Laryngoscope 102: 256-260, 1992.
18. Pigman EC, and Scott JL. Angioedema in the emergency department: The impact of angiotensin-converting enzyme inhibitors. Am J Emerg Med 11: 350-354, 1993.
19. Bluestein HM, Hoover TA, Banerji AS, et al. Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann Allergy Asthma Immunol 103: 502-507, 2009.
20. Caldeira D, David C, and Sampaio C. Tolerability of angiotensin- receptor blockers in patients with intolerance to angiotensin- converting enzyme inhibitors: A systematic review and meta-analysis. Am J Cardiovasc Drugs 12: 263-277, 2012.
21. Byrd JB, Woodard-Grice A, Stone E, et al. Association of angiotensin- converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy 65: 1381-1387, 2010.
22. Malde B, Regalado J, and Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 98: 57-63, 2007.
23. Piller LB, Ford CE, Davis BR, et al. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 8: 649-656, 2006.
24. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 303: 232-237, 2002.
25. Anderson MW, and deShazo RD. Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: The effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. J Allergy Clin Immunol 85: 856-858, 1990.
26. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 359: 2088-2089, 2002.
27. Lefebvre J, Murphey LJ, Hartert TV, et al. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 39: 460-464, 2002.
28. Byrd JB, Adam A, and Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 26: 725-737, 2006.
29. Byrd JB, Shreevatsa A, Putlur P, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol 120: 403-408, 2007.
30. Gainer JV, Nadeau JH, Ryder D, and Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 98: 283-287, 1996.
31. Gainer JV, Stein CM, Neal T, et al. Interactive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension 37: 46-51, 2001.
32. Rosenbaum DA, Pretorius M, Gainer JV, et al. Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin. Arterioscler Thromb Vasc Biol 22: 1023-1028, 2002.
33. Chiu AG, Newkirk KA, Davidson BJ, et al. Angiotensin-converting enzyme inhibitor-induced angioedema: A multicenter review and an algorithm for airway management. Ann Otol Rhinol Laryngol 110: 834-840, 2001.
34. Gabb GM, Ryan P, Wing LM, and Hutchinson KA. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 26: 777-782, 1996.
35. Al-Khudari S, Loochtan MJ, Peterson E, and Yaremchuk KL. Management of angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope 121: 2327-2334, 2011.
36. Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitorrelated angioedema. J Hypertens 29: 2273-2277, 2011.
37. Fast S, Henningsen E, and Bygum A. Icatibant is a new treatment option in life-threatening angioedema triggered by angiotensin- converting enzyme inhibitor. Ugeskrift Laeger 173: 2574-2575, 2011.
38. Karim MY, and Masood A. Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema. J Allergy Clin Immunol 109: 370-371, 2002.
39. Warrier MR, Copilevitz CA, Dykewicz MS, and Slavin RG. Fresh frozen plasma in the treatment of resistant angiotensinconverting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol 92: 573-575, 2004.
40. Hassen GW, Kalantari H, Parraga M, et al. Fresh frozen plasma for progressive and refractory angiotensin-converting enzyme inhibitor-induced angioedema. J Emerg Med 2012. DOI: 10.1016/j.jemermed.2012.07.055 (Epub ahead of print.)
41. Stewart M, and McGlone R. Fresh frozen plasma in the treatment of ACE inhibitor-induced angioedema. BMJ Case Rep 2012. DOI: 10.1136/bcr-2012-006849 (Epub ahead of print.)
42. Nielsen EW, and Gramstad S. Angioedema from angiotensinconverting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 50: 120-122, 2006.
43. Gelee B, Michel P, Haas R, et al. Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate. Rev Med Intern 29: 516-519, 2008.
44. Riedl MA. Update on the acute treatment of hereditary angioedema. Allergy Asthma Proc 32: 11-16, 2011.
45. Zuraw BL. HAE therapies: Past present and future. Allergy Asthma Clin Immunol 6:23, 2010.
46. Gallitelli M, and Alzetta M. Icatibant: A novel approach to the treatment of angioedema related to the use of angiotensinconverting enzyme inhibitors. Am J Emerg Med 30:1664.e1- 1664.e2, 2012.
47. Javaud N, Fain O, Bernot B, et al. Bradykinin-mediated angioedema secondary to angiotensin converting enzyme: Initiate treatment from the prehospital phase. Ann Fr Anesth Reanim 30: 848-850, 2011.
48. Illing EJ, Kelly S, Hobson JC, and Charters S. Icatibant and ACE inhibitor angioedema. BMJ Case Rep 2012. DOI: 10.1136/bcr- 2012-006646 (Epub ahead of print.)